key: cord-0745552-7btpkjbe
authors: Dunay, Megan A; McClain, Sarah L; Holloway, Rick L; Norris, Sarah L W; Bendixsen Randall, Talie; Mohr, Caitlin E; Sasaki, Brent H; Coones, Joseph A; Vietri, Nicholas J
title: Pre-Hospital Administration of Remdesivir during a SARS-CoV-2 Outbreak in a Skilled Nursing Facility
date: 2021-08-19
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab715
sha: 1b62505e5bed91c3c4a64067d66cebb5a687be4d
doc_id: 745552
cord_uid: 7btpkjbe

Completion of a 5-day course of remdesivir was associated with approximately 17-fold increased odds of survival among a sample of 54 nursing home residents with SARS-CoV-2 infection during the course of an outbreak from October to December, 2020. Remdesivir was well-tolerated; administration was logistically feasible in a pre-hospital environment.

M a n u s c r i p t 4 Background Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) causes COVID-19, with manifestations ranging from asymptomatic viral carriage to severe disease. Risk factors for severe disease include advanced age, multimorbidity, diabetes mellitus (DM) and obesity. [1] [2] Older adults and those residing in Long Term Care Facilities (LTCF) are among the most severely impacted, with 658,169 total confirmed cases and 133,414 COVID-attributed deaths among residents per Centers for Medicare and Medicaid Services (CMS) at the time of this writing. [3] [4] [5] In October 2020, remdesivir received FDA-approval for the treatment of hospitalized patients with COVID-19. 6 Remdesivir is a nucleotide analogue, which inhibits viral RNAdependent RNA polymerase. [6] [7] [8] The majority of clinical experience with remdesivir derives from use in acute care, where it has been shown to reduce time to recovery in patients hospitalized with COVID-19. [8] [9] [10] [11] While positive trends in mortality have been observed, no statistically significant mortality reduction has been proven with remdesivir in hospitalized patients. [8] [9] [10] [11] This report describes our experience administering a 5-day course of remdesivir to SNF residents during a COVID-19 outbreak, prior to vaccine availability. This off-label use was undertaken in the context of a large-scale outbreak in a high-prevalence region. Our team sought to treat residents as promptly as possible following diagnosis.

The Idaho State Veteran's Home-Boise (ISVH-B) is a state-owned, 124-bed SNF. Most rooms are double-occupancy, with restrooms shared by as many as four residents. At the time of the outbreak, the facility census was 88.

A c c e p t e d M a n u s c r i p t 5 SARS-CoV-2 surveillance testing was implemented for all residents and staff beginning in May 2020, pursuant to CMS and state regulations. Testing frequency was adjusted by countylevel COVID-19 prevalence. Both polymerase chain reaction (PCR; Applied Biosystems TaqPath COVID-19) and rapid antigen (Becton Dickinson, BD Veritor Plus) testing were employed in twice weekly surveillance from July 2020 through January 2021.

Patients diagnosed with SARS-CoV-2 on or after October 14, 2020 were treated at the LTCF using a standardized set of supportive measures and were transferred to a higher level of care if needed, depending upon disease severity and if congruent with their goals of care. Residents who developed respiratory distress but did not desire transfer to acute care were treated with dexamethasone 6mg PO daily for 5-days, as well as mometasone furoate inhalation. Residents with secondary bacterial pneumonia were treated with amoxicillin/clavulanate; those with venous thromboembolism were treated with enoxaparin. Residents were considered to survive SARS-CoV-2 infection if they were alive 28-days after diagnosis. Baseline demographic and clinical characteristics of patients were collected (Table 1) . Differences in age and BMI between survivors and non-survivors were tested by Student t-tests. Logistic regression analyses were completed individually against the dependent variable of death due to COVID-19. A stepwise logistic regression was also conducted to determine which of the independent variables were most significantly associated with the dependent outcome when considered simultaneously. The cutoff probability for entry into the model was set to p=0.20, while the cutoff probability for remaining in the model was p=0.05. All analyses were performed using SAS Version 9.4.

Baseline characteristics of patients are summarized in Table 1 . Residents who survived COVID-19 were slightly younger than those who died (p=0.0691). All residents who died did not desire cardiopulmonary resuscitation and indicated a code status of "Do Not Resuscitate (DNR)." Of the residents who survived, 35(77.8%) indicated DNR code status. Most patients in this study were asymptomatic (59.3%). Among those who were symptomatic at diagnosis, a higher mortality rate was observed (88.9%). Fourteen of the symptomatic patients received remdesivir, of whom 10 (71.4%) survived.

Results of logistic regression are summarized in Table 2 Age, weight, other co-existing conditions and concomitant therapies were not found to be significant predictors of mortality (Table 2) .

One resident developed transaminitis following receipt of two doses of remdesivir. He had baseline elevation of liver enzymes secondary to congestive hepatopathy. Transaminitis following remdesivir administration was mild, compared to baseline values, and occurred in the context of septic shock related to COVID-19; this resident died of septic shock.

One resident expired within several hours of receipt of a single dose of remdesivir. This resident was noted to have signs and symptoms of septic shock several hours prior to remdesivir administration but did not desire hospitalization or aggressive interventions. A compassionate dose of remdesivir was given, per the family's wishes.

Three residents developed hyperkalemia while receiving remdesivir; of these, one required transfer to a higher level of care for management. Hyperglycemia was observed in many residents receiving remdesivir and the supportive measures described above.

Dexamethasone was implicated in most cases of hyperglycemia.

Observational data from this cohort demonstrate nearly 17-fold increased odds of survival at 28-days among SNF residents receiving a 5-day course of remdesivir. SNF residents were administered remdesivir promptly upon diagnosis of SARS-CoV-2 infection, with an A c c e p t e d M a n u s c r i p t 8 average of 2.4 days from diagnosis to remdesivir-initiation. Prompt remdesivir administration in a pre-hospital setting, regardless of symptoms, is a novel approach to COVID-19 management and is hypothesized to account for the profound survival benefit observed here, which has not been observed in other studies of remdesivir. [8] [9] [10] [11] While our approach was novel, early treatment with remdesivir has been efficacious in experimental models of viral infection, and early antiviral therapy is well-aligned with the treatment paradigm of influenza in LTCF. 12 Antiviral therapy for influenza exerts greatest clinical benefit when initiated as soon as possible after symptom onset. 12 Reduction in influenza transmission has also been observed in LTCF settings with early antiviral treatment, and it is As reasonable to hypothesize a similar effect with early initiation of remdesivir for SARS-CoV-2.

the outbreak progressed, we initiated remdesivir more quickly, often on the day of diagnosis.

That said, receipt of remdesivir within 48-hours of diagnosis did not reach statistical 0.0539), likely due to small sample size. significance (p= Increased mortality was observed among our patients with diabetes, consistent with findings in other settings. 4, 13 In our sample, completion of a 5-day course of remdesivir among residents with diabetes was protective, even when accounting for the influence of diabetes in reducing survival.

In addition to demonstrating clinical benefit, this study demonstrates the plausibility of administering remdesivir in the LTCF setting. The utilization of elastomeric balls for intravenous infusion obviated the need for IV pumps. No complications related to use of the infusion device were encountered. Adverse events were uncommon.

This observational study is limited by small sample size, and by the homogeneity in gender and race among the residents observed: the population of the ISVH-B is predominantly male and white. Due to the small sample size, extended statistical analyses, such as exploration of interactions between independent variables, were not possible. M a n u s c r i p t 9 This study required resources not always available in LTCF. Coordination with an infusion pharmacy and frequent deliveries are critical due to the short stability of remdesivir.

Nurses skilled in IV placement and monitoring, as well as phlebotomy staff, were essential.

Finally, close monitoring of clinical status through daily physician rounding is requisite.

Asymptomatic patients accounted for the majority of patients observed in this study, perhaps contributing to the profound mortality benefit described. Thus, the role of antivirals in asymptomatic positive patients is unclear but should be considered in LTCF outbreak contexts.

While vaccination stands to mitigate SARS-CoV-2 severity among LTCF populations, challenges in vaccine uptake and emerging variants remain, analogous to seasonal influenza. Additionally, the extent and duration of protection conferred by vaccination in frail, multimorbid older adults remains to be seen. Thus, access to and guidelines for use of, broad-spectrum antiviral agents with activity against SARS-CoV-2 and other respiratory viruses of pandemic potential are of paramount importance.

M a n u s c r i p t 12 

Factors associated with COVID-19-related death using OpenSAFELY

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Nursing Home Care in Crisis in the Wake of COVID-19

Risk Factors Associated With Mortality Among Residents With Coronavirus Disease 2019 (COVID-19) in Long-term Care Facilities in Ontario

Characteristics of U.S. Nursing Homes with COVID-19 Cases

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Remdesivir for the Treatment of Covid-19 -Final Report

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza

Risk Factors Associated with All-Cause 30-Day Mortality in Nursing Home Residents with COVID-19

A c c e p t e d M a n u s c r i p t 11 M a n u s c r i p t 14